H.C. Wainwright Lowers CalciMedica Rating to Neutral After IDMC Halts Phase 2 KOURAGE Trial
H.C. Wainwright downgraded CalciMedica (NASDAQ:CALC) from Buy to Neutral following the company’s decision to discontinue its Phase 2 KOURAGE study after an Independent Data Monitoring Committee flagged a safety signal. The stock has plunged more than three-quarters in the last week, and the company is analyzing unblinded data while discussing poten…